Brain Tumor Drugs Companies, Innovation and Product Evolution

Brain Tumor Drugs Market Top Vendors and Their Offerings

Merck & Co.

Headquarters: Rahway, U.S.
Brain Tumor Drugs: Temodar

F. Hoffmann-La Roche

Headquarters: Basel, Switzerland
Brain Tumor Drugs: Avastin

Servier

Headquarters: Paris, France
Brain Tumor Drugs: Voranigo

Novartis AG

Headquarters: Basel, Switzerland
Brain Tumor Drugs: Afinitor and Tafinlar + Mekinist

Pfizer Inc.

Headquarters: New York, U.S.
Brain Tumor Drugs: Inlyta

Day One Biopharma

Headquarters: Brisbane, U.S.
Brain Tumor Drugs: Ojemda

Bayer AG

Headquarters: Leverkusen, Germany
Brain Tumor Drugs: Stivarga and Nexavar

Chimerix

Headquarters: Durham, U.S.
Brain Tumor Drugs: Modeyso

Eisai Co., Ltd.

Headquarters: Tokyo, Japan
Brain Tumor Drugs: Lenvima

Arbor Pharmaceutical

Headquarters: Atlanta, U.S.
Brain Tumor Drugs: Gliadel Wafer

Brain Tumor Drugs Market Value Chain Analysis

R&D

• The R&D of the brain tumor drugs focuses on the development of targeted therapies and next-generation immunotherapies to treat aggressive brain cancers.
• Key players: Novartis, Roche, AstraZeneca.

Clinical Trials and Regulatory Approvals

• The safety, efficacy in controlling the disease progression, and risk-benefit ratio are evaluated in the clinical trials and regulatory approvals of the brain tumor drugs.
• Key players: Chimerix, Servier, Day One Biopharma.

Formulation and Final Dosage Preparation

• The active pharmaceutical ingredients (API) and excipients are combined to develop various formulations such as oral capsules, liquid suspensions, and intravenous infusion, which are included in the formulation and final dosage preparation of brain tumor drugs.
• Key players: Genentech, Merck & Co., Arbor Pharmaceuticals.

Packaging and Serialization

• The packaging and serialization of the brain tumor drugs involves the use of high-density polyethylene bottles or sterile vials as tamper-evident primary containers, and secondary packing integrating the unique 2D data matrix barcodes to ensure product integrity and traceability.
• Key players: Novartis, Roche, Pfizer.

Distribution to Hospitals, Pharmacies

• The specialized cold chain networks and specialty pharmacy providers are involved in the distribution of the brain tumor drugs to hospitals and pharmacies.
• Key players: Arbor Pharmaceuticals, Roche, Servier.

Patient Support and Services

• Access to nurse navigators, reimbursement support, and financial assistance are provided in the patient support and services for the brain tumor drugs.
• Key players: Roche, Novartis, Merck & Co.

Market Growth

The global brain tumor drugs market size was estimated at USD 2.33 billion in 2025 and is predicted to increase from USD 2.55 billion in 2026 to approximately USD 5.69 billion by 2035, expanding at a CAGR of 9.34% from 2026 to 2035.

What are the Recent Developments in the Brain Tumor Drugs Market?

• In January 2026, to modernize the treatment of glioblastoma, a new combination therapy was launched by the collaboration between the UNC Eshelman School of Pharmacy and the UNC School of Medicine, which combined a chemotherapy drug with a chemical called EdU, where it provided extraordinary survival rates and cancer reduction.
• In July 2025, MT-125, a medication developed by The Wertheim UF Scripps Institute, was announced to have received FDA approval, promoting its clinical trial, with an aim to be the first line of treatment option for glioblastoma, the most deadly form of brain cancer.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com